⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 16, 2016Journal of Nuclear MedicineOpen Access

PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with ¹⁷⁷Lu-Labeled PSMA-617

Clemens Kratochwil Frederik L. Giesel M. Stefanova Martina Benešová Marcus Bronzel Ali Afshar‐Oromieh Walter Mier Matthias Eder Klaus Kopka Uwe Haberkorn

View Full Paper

Ask AI

Bookmark

Share

Abstract

(177)Lu-PSMA-617 is a promising new option for therapy of mCRPC and deserves more attention in larger prospective trials.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kratochwil et al. (2016) studied this question.

synapsesocial.com/papers/69dc54ebd74bf23813c0fe26 https://doi.org/10.2967/jnumed.115.171397

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Impact of PSMA PET/CT Staging on Long-Term Outcomes in Patients with Clinically Localized Prostate Cancer: Results of a Large Single-Center CohortJournal of Nuclear Medicine · 2026
2Botulinum Toxin Plus Transdermal Scopolamine Reduces Salivary Gland Uptake in Patients Undergoing Tandem Radiopharmaceutical Therapy with [ 225 Ac]Ac- and [ 177 Lu]Lu-PSMA RadioligandsJournal of Nuclear Medicine · 2026
3Predicting [ 90 Y]Y-FAPI-46 Tumor Absorbed Dose from Single-Time-Point [ 68 Ga]Ga-FAPI-46 PET/CT ImagingJournal of Nuclear Medicine · 2026
4Prostate-Specific Membrane Antigen PET/CT Complements MRI for Focal Therapy Selection in Prostate Cancer: A Whole-Mount Histopathologic StudyJournal of Nuclear Medicine · 2026
5Patterns of Progression on Posttreatment Imaging During [ 177 Lu]Lu-PSMA Radiopharmaceutical TherapyJournal of Nuclear Medicine · 2026

Should Molecular Subtype Influence the Interpretation of Serial 68 Ga-HER2 PET/CT During Neoadjuvant Therapy?Journal of Nuclear Medicine · 2026
Role of [ 18 F]F-Fluciclovine PET/CT in Patients with Biochemical Recurrence of Prostate Cancer and Negative PSMA PET Results: A Single-Center StudyJournal of Nuclear Medicine · 2026
Symptomatic Hyperkinetic Gallbladder: An Unrecognized Indication for CholecystectomyJournal of Nuclear Medicine · 2026
18 F-BMS-986192 PET to Predict Durable Response to Nivolumab in NSCLC: A Novel Approach Beyond PD-L1 ImmunohistochemistryJournal of Nuclear Medicine · 2026
TBR max After FDA Approval of [ 18 F]FET PET: 1 Name, 2 MeasurementsJournal of Nuclear Medicine · 2026

More from Journal of Nuclear Medicine

More from Heidelberg University

More from University Hospital Heidelberg

More from German Cancer Research Center

More from ABX-CRO Advanced Pharmaceutical Services (Germany)